Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study

SAN DIEGO, March 22, 2022 /PRNewswire/ — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the Phase 3, RESUME-1, clinical study of tolperisone for the relief of muscle spasm associated with acute, painful…

Click here to view original post